The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
GR Tundo, D Sbardella, AM Santoro, A Coletta… - Pharmacology & …, 2020 - Elsevier
Abstract Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that
sustains proteostasis network under a large variety of physiopathological conditions. Its …
sustains proteostasis network under a large variety of physiopathological conditions. Its …
The Rise of Boron-Containing Compounds: Advancements in Synthesis, Medicinal Chemistry, and Emerging Pharmacology
Boron-containing compounds (BCC) have emerged as important pharmacophores. To date,
five BCC drugs (including boronic acids and boroles) have been approved by the FDA for …
five BCC drugs (including boronic acids and boroles) have been approved by the FDA for …
Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids
Pediatric hepatoblastoma is the most common primary liver cancer in infants and children.
Studies of hepatoblastoma that focus exclusively on tumor cells demonstrate sparse somatic …
Studies of hepatoblastoma that focus exclusively on tumor cells demonstrate sparse somatic …
Revisiting proteasome inhibitors: molecular underpinnings of their development, mechanisms of resistance and strategies to overcome anti-cancer drug resistance
C Leonardo-Sousa, AN Carvalho, RA Guedes… - Molecules, 2022 - mdpi.com
Proteasome inhibitors have shown relevant clinical activity in several hematological
malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient …
malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient …
Deubiquitinase inhibitor b-AP15 activates endoplasmic reticulum (ER) stress and inhibits Wnt/Notch1 signaling pathway leading to the reduction of cell survival in …
Y Ding, X Chen, B Wang, B Yu, J Ge - European journal of pharmacology, 2018 - Elsevier
Abstract b-AP15, a potent and selective inhibitor of the ubiquitin-specific peptidase 14
(USP14), displays in vitro and in vivo antitumor abilities on some types of cancer cells …
(USP14), displays in vitro and in vivo antitumor abilities on some types of cancer cells …
A sensitive and simple targeted proteomics approach to quantify transcription factor and membrane proteins of the unfolded protein response pathway in glioblastoma …
CDL Nguyen, S Malchow, S Reich, S Steltgens… - Scientific reports, 2019 - nature.com
Many cellular events are driven by changes in protein expression, measurable by mass
spectrometry or antibody-based assays. However, using conventional technology, the …
spectrometry or antibody-based assays. However, using conventional technology, the …
Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells
Hepatocellular carcinoma (HCC) is one of the common malignancies and is an increasingly
important cause of cancer death worldwide. Surgery, chemotherapy, and radiation therapy …
important cause of cancer death worldwide. Surgery, chemotherapy, and radiation therapy …
Modulation of proteasome subunit selectivity of syringolins
K Tatsumi, S Kitahata, Y Komatani, A Katsuyama… - Bioorganic & Medicinal …, 2024 - Elsevier
Abstract Development of selective or dual proteasome subunit inhibitors based on syringolin
B as a scaffold is described. We focused our efforts on a structure–activity relationship study …
B as a scaffold is described. We focused our efforts on a structure–activity relationship study …
Enhanced intracellular accumulation and cytotoxicity of bortezomib against liver cancer cells using N-stearyl lactobionamide surface modified solid lipid nanoparticles
Asialoglycoprotein receptors (ASGPRs) are highly expressed on hepatocytes and have
been used for liver-targeted delivery and hepatocellular carcinoma (HCC) therapy …
been used for liver-targeted delivery and hepatocellular carcinoma (HCC) therapy …
Pharmacological or trib3-mediated suppression of atf4 transcriptional activity promotes hepatoma cell resistance to proteasome inhibitor bortezomib
T Örd, D Örd, MU Kaikkonen, T Örd - Cancers, 2021 - mdpi.com
Simple Summary Proteasome inhibitors are currently used in the treatment of certain blood
cancers, and clinical trials to treat solid tumors, including liver cancer, have also been …
cancers, and clinical trials to treat solid tumors, including liver cancer, have also been …